MabCure, Inc (MBCI) Fair Value & Analysis
Technology · US · Market cap $234
MabCure, Inc
MBCI · US
Fair value as of: Aug 19, 2026
From 1 valuation models · updated today
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range $0.0001 – $0.0151 · the $0.0003 price screens below the $0.0003 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
MabCure, Inc (MBCI) currently trades at $0.0003, while our model-based Fair Value estimate is $0.0003, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 37/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $500K. Fundamentals as of Aug 19, 2026
The share trades about 40% below its 52-week high, currently above its 200-day average. For context, the median of 10 Technology peers we cover trades at -6% fair-value upside, at 0%, MBCI screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when MBCI reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 100
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers.
Full company description
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2007 – FY2011 · reported fiscal years
MabCure, Inc reported revenue of $500K in FY2011 versus $0 in FY2008. Reported net income was −$12.5M in FY2011.
Watch MBCI: get an alert when its fair value changes →
Peer Group
Solar · 116 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Solar stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| First Solar, Inc FSLR | $217.85 | $392.12 | +80% |
| Nextpower Inc NXT | $103.67 | $69.61 | -33% |
| Waaree Energies Limited WAAREEENER | ₹2,668 | ₹2,709 | +2% |
| Tongwei Co 600438 | ¥12.89 | ¥12.13 | -6% |
| Jinko Solar Co 688223 | ¥4.52 | ¥6.47 | +43% |
| Enphase Energy, Inc ENPH | $40.77 | $24.15 | -41% |
| CSI Solar Co 688472 | ¥10.28 | ¥6.76 | -34% |
| Hengdian Group 002056 | ¥22.35 | ¥31.86 | +43% |
| Premier Energies Limited PREMIERENE | ₹1,017 | ₹648.94 | -36% |
| Trina Solar Co 688599 | ¥13.64 | ¥7.97 | -42% |
Compare MabCure, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is MabCure, Inc (MBCI) overvalued or undervalued?
What is the fair value of MBCI?
What is the quality score of MBCI?
What is the revenue of MabCure, Inc (MBCI)?
What is the net profit margin of MBCI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MabCure, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.